Background: Major histocompatibility complex class I (MHC I) plays a critical role in immune surveillance by binding peptides derived from intracellular proteins and presenting them on the cell surface for recognition by CD8+ T cells. Loss or downregulation of MHC I expression has been identified as a key mechanism of immune evasion in cancers. Here, we evaluated MHC I expression and outcomes in all subtypes of breast cancer (BC).
Publications
MHC Class I Expression and Outcomes in Breast Cancer in the Real-World Clinico-Genomic Data and the FinXX Trial
– Caris Life Sciences